The Effects of nicotine in dermal plaster on cognitive functions in patients with alzheimers disease

Dementia and Geriatric Cognitive Disorders

Volumn 7, Issue 1, 1996, Pages 47-52

  Snaedal, J ^a   Johannesson, T ^a   Jornson, J E ^a   Gylfadottir, G ^a  

^a UNIVERSITY OF ICELAND   (Iceland)

Author keywords

Administration; Alzheimer s disease; Cutaneous; Nicotine; Transdermal application

Indexed keywords

GANGLION STIMULATING AGENT; NICOTINE;

AGED; ALZHEIMER DISEASE; AMNESIA; ARTICLE; ATTENTION; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; FEMALE; HUMAN; MALE; MEMORY; NAUSEA; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; RANDOMIZED CONTROLLED TRIAL; SWEATING; TRANSDERMAL DRUG ADMINISTRATION; VERBAL BEHAVIOR;

ADMINISTRATION, CUTANEOUS; AGED; ALZHEIMER DISEASE; COGNITION; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MEMORY; NICOTINE; NICOTINIC AGONISTS; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; SINGLE-BLIND METHOD;

EID: 0030049572     PISSN: 14208008     EISSN: 14219824     Source Type: Journal    
DOI: 10.1159/000106852     Document Type: Article

References (21)

1. Drachman DA. Sahakian BJ: Effects of cholinergic agents on human learning and memory; in Barbeau A. Growden JH. Wurtman RJ (eds): Nutrition and the Brain. New York, Raven Press. 1979, vol 5. pp 351-366.
2. Eagger SA, Levy R, Sahakian BJ: Tacrine in Alzheimer's disease. Lancet 1991:337:989-992.
3. Gauthier S, Bouchard R, Lamentagnc A, Bailey P, Bergman H, Ratner J, et al: Tctrahydroami-noacridine-lecithin combination treatment in patients with intermediate stage Alzheimer’s disease. N Engl J Med 1990:322:1272-1276.
4. Davis KL, Thai IJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, et al: A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med 1992; 327:1253-1259.
5. Aubert I, Araujo DM, Cécyre D, Robitaille Y, Gauthier S, Quirion R: Comparative alteration of nicotine and muscarinic binding sites in Alzheimer's and Parkinson’s disease. J Neuro-chem 1992:58:529-541.
6. Wonnacott S, Drasdo A, Sanderson E, Rowell P: Presynaptic nicotine receptors and the modulation of transmitter release. Ciba Found Svmp 1990;152:87-105.
7. Decker MW, Majchrzak MJ, Anderson DJ: Effects of nicotine on spatial memory deficits in rats with septal lesions. Brain Res 1992;572: 281-285.
8. Buccafusco JJ, Jackson WJ: Beneficial effects of nicotine administered prior to a delayed mathing-to-samplc task in young and aged monkeys. Neurobiol Aging 1991:12:233-238.
9. Sahakian B, Jones G, Levy R, Gray J, Warbur-ton DM: The effects of nicotine on attention, information processing and short-term memory' in patients with dementia of the Alzheimer's type. Br J Psychiatry 1989:154:797-800.
10. Jones GMM, Sahakian BI, Levy R. Warburton DM, Gray JA: Effects of acute subcutaneous nicotine on attention, information processing and short-term memory' in Alzheimer’s disease. Psychopharmacology 1992:108:485-494.
11. Graves AB, van Duijn CM, Chandra V, Frati-glioni L, Heyman A, Jorm AF, Kokmen E, Kondo K, Motimer JA, Rocca WA, Shalat SL, Soinincn H, Hofman A: Alcohol and tobacco consumption as risk factors for Alzheimer’s disease: A collaborative re-analysis of case-con-trol studies. Int J Epidemiol 1991;20(suppl. 2): 48-57.
12. Le Houezec J, Benowitz NL: Basic and clinical psychopharmacology of nicotine. Clin Chest Med 1991:12:681-699.
13. McKhann G, Drachman D, Folstcin M: Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS/ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 1984;34:939-944.
14. Spreen O, Strauss E: A compendium of neuropsychological tests. Oxford, Oxford University Press. 1991.
15. Hughes CP, Berg L, Danzigcr WL, Coben LA, Martin RL: A new clinical scale for the staging of dementia. Br J Psychiatry 1982:140:566-572.
16. Comroe JH: The pharmacological actions of nicotine. Ann NY Acad Sci 1960:90:48-51.
17. Porchct HC, Benowitz NL, Shciner LB: Pharmacodynamic models for tolerance: Application to nicotine. J Pharmacol Exp Ther 1989: 244:231-236.
18. Routtenberg A: The two-arousal hypothesis: Reticular formation and limbic system. Psychology Rev 1968;75:51-80.
19. Chesselt MF: Presynaptic regulation of neuro-transmilter release in the brain. Facts and hypothesis. Neuroscience 1984;12:347-375.
20. Muramoto O, Sugishita M, Ando K: Cholinergic system and constructional praxis: A further study of physostigmine in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 1984:47:485-491.
21. Working Group for the Study of Transderntal Nicotine in Patients with Coronary Artery Disease: Nicotine replacement therapy for patients with coronary artery disease. Arch Intern Med 1994;154:989-995.